Status:
WITHDRAWN
Japanese Phase 1 Study of BMS-844203 (CT322)
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Neoplasms
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
The purpose of this clinical study is to evaluate the safety and tolerability of CT-322 monotherapy to determine the recommended dose for phase II and subsequent studies
Eligibility Criteria
Inclusion
- Advanced or metastatic solid tumors for whom the standard of care is ineffective or inappropriate
- Life expectancy of at least 3 months
- Eastern Cooperative Oncology Group performance 0-1
Exclusion
- Subject has uncontrolled diabetes or hypertension
- Clinical significant bleeding diathesis or coagulopathy
- Thrombotic or embolic cerebrovascular accident
Key Trial Info
Start Date :
November 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01146171
Start Date
November 1 2013
End Date
January 1 2015
Last Update
February 7 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Osaka-Sayama-Shi, Osaka, Japan, 5898511